Vogenx (NASDAQ:VOGX) Stock Gets Downgrade from Wall Street Zen

Vogenx (NASDAQ:VOGX – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

VOGX has been the topic of a number of other research reports. Zacks Research raised shares of Vogenx to a “hold” rating in a research note on Monday, September 28th. Weiss Ratings started coverage on Vogenx in a research note on Monday, November 9th. They issued a “sell (e-)” rating for the company. WBB Securities initiated coverage on Vogenx in a report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price objective on the stock. Finally, JonesTrading started coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vogenx presently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Get Our Latest Analysis on Vogenx

Vogenx Stock Performance

VOGX opened at $16.67 on Friday. The firm has a market cap of $247.55 million and a P/E ratio of -79.38. The firm has a 50 day moving average of $22.03. Vogenx has a 1-year low of $12.95 and a 1-year high of $38.41.

Vogenx (NASDAQ:VOGX – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, equities analysts predict that Vogenx will post -0.61 earnings per share for the current fiscal year.

Vogenx Company Profile

(Get Free Report)

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.

Recommended Stories

Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.